Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: a nationwide cross-sectional study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of proper antiviral agents may be challenging among elderly patients due to relevant comorbidities, comedications, and drug-drug interaction (DDI). It may be helpful to understand the current demographic status and comorbidities of CHC patients in the country. Methods: Patients aged ≥ 18 years and diagnosed with CHC (KCD-7 code B18.2) were extracted from the Korean Health Insurance Review & Assessment Service database in 2018. Data on comorbidities and comedications were assessed and potential DDIs were analyzed. Results: A total of 50,476 patients with CHC, with a mean age of 60.3 years and 46.7% male patients were identified. The proportion of patients with cirrhosis, hepatocellular carcinoma, and liver transplantation was 6.0%, 4.1%, and 0.3%, respectively and 37.2% of patients were more than 65 years of age. The three most common comorbidities were diseases of the digestive system (83.7%), respiratory system (58.2%), and musculoskeletal system and connective tissue (57.6%). The three most common comedications were analgesics (91.6%), gastrointestinal agents (85%), and antibacterials (80.3%). Lipid-lowering agents and anticonvulsants were prescribed in 28.5% and 14.8% of patients. Rate of potential DDI for contraindication was 2.2%, 13.1%, and 15.6% with sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and glecaprevir/pibrentasvir. Conclusions: With the increasing age of patients with CHC, comorbidity, comedication, and potential DDI should be considered when choosing antivirals in Korea. Sofosbuvir-based regimens showed favorable DDI profiles among Korean patients.
Abstract
Background/Aims: Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of proper antiviral agents may be challenging among elderly patients due to relevant comorbidities, comedications, and drug-drug interaction (DDI). It may be helpful to understand the current demographic status and comorbidities of CHC patients in the country. Methods: Patients aged ≥ 18 years and diagnosed with CHC (KCD-7 code B18.2) were extracted from the Korean Health Insurance Review & Assessment Service database in 2018. Data on comorbidities and comedications were assessed and potential DDIs were analyzed. Results: A total of 50,476 patients with CHC, with a mean age of 60.3 years and 46.7% male patients were identified. The proportion of patients with cirrhosis, hepatocellular carcinoma, and liver transplantation was 6.0%, 4.1%, and 0.3%, respectively and 37.2% of patients were more than 65 years of age. The three most common comorbidities were diseases of the digestive system (83.7%), respiratory system (58.2%), and musculoskeletal system and connective tissue (57.6%). The three most common comedications were analgesics (91.6%), gastrointestinal agents (85%), and antibacterials (80.3%). Lipid-lowering agents and anticonvulsants were prescribed in 28.5% and 14.8% of patients. Rate of potential DDI for contraindication was 2.2%, 13.1%, and 15.6% with sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and glecaprevir/pibrentasvir. Conclusions: With the increasing age of patients with CHC, comorbidity, comedication, and potential DDI should be considered when choosing antivirals in Korea. Sofosbuvir-based regimens showed favorable DDI profiles among Korean patients.
참고문헌 (19)
- Wei L, "Hepatitis C viral infection disease burden in Asia", Value Outcomes Spotlight, 1, pp.16~18 (2015)
- "Korean Association for the Study of the Liver" (2020)[URL]
- Kondili LA, "Absolute targets for HCV elimination and national health policy paradigms : foreseeing future requirements", Liver Int, 41, pp.649~655 (2021)
- Hye-Lin Kim, "A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective", Clinical and Molecular Hepatology, 28(1), pp.91~104 (2022), 대한간학회[DOI]
- Chhatwal J, "Hepatitis C virus re-treatment in the era of direct-acting antivirals : projections in the USA", Aliment Pharmacol Ther, 47, pp.1023~1031 (2018)
- Hae-Sook Shon, "Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012", Clinical and Molecular Hepatology, 21(3), pp.249~256 (2015), 대한간학회
- Hae-Sook Sohn, "Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with a High Prevalence of HCV in the Republic of Korea in 2013", Gut and Liver, 10(1), pp.126~132 (2016), 거트앤리버 소화기연관학회협의회
- 정정화, "Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study", Gut and Liver, 15(2), pp.295~306 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Devarbhavi H, "Drug-induced liver injury : Asia Pacific Association of Study of Liver consensus guidelines", Hepatol Int, 15, pp.258~282 (2021)
- Mangia A, "Drug-drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents : insights from a real-world study", Int J Environ Res Public Health, 18, pp.7144~ (2021)
- "Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy" (2022)[URL]
- World Health Organization(WHO), "Interim Guidance for Country Validation of Viral Hepatitis Elimination", WHO, ~ (2021)
- Kim L, "A guide for the utilization of health insurance review and assessment service national patient samples", Epidemiol Health, 36, pp.e2014008~ (2014)
- Kim J, "The cross-validation of Samsung Medical Center’s clinical terminology to KCD-7 and SNOMED to ICD-10 mappings", SNOMED CT Expo (2020)
- Steiner S, "Update on Hepatitis C" (2017), IntechOpen
- Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
- Mohammed Abdul MK, "Hepatitis C virus in the elderly in the direct-acting antiviral era : from diagnosis to cure", Curr Treat Options Infect Dis, 12, pp.296~309 (2020)
- Salive ME, "Multimorbidity in older adults", Epidemiol Rev, 35, pp.75~83 (2013)
- Chang KC, "Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan", Sci Rep, 11, pp.13543~ (2021)